TD Asset Management
SEPN

TD Asset Management’s Septerna Inc SEPN Stock Holding History

TD Asset Management’s Portfolio SEPN Stock Details SEPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-69,460
Closed -$1.59M – 1284
2024
Q4 		$1.59M Buy
+69,460
New +$1.64M ﹤0.01% 1055

Other funds holding SEPN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $136M AUM 328.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TD Asset Management's SEPN Position: Q1 2025 in Review

TD Asset Management sold out of Septerna Inc (SEPN) in Q1 2025, closing a stake of 69,460 shares — an estimated $1.59M sold.

TD Asset Management first reported a position in SEPN in Q4 2024 and held it in 1 quarter. The position peaked at $1.59M in Q4 2024. 71 funds tracked by Wall St. Rank hold SEPN as of Q1 2025.

  • TD Asset Management reported no remaining Septerna Inc position as of Q1 2025 after selling out during the quarter.
  • TD Asset Management sold 69,460 Septerna Inc shares in Q1 2025, an estimated $1.59M.
  • TD Asset Management first reported a position in Septerna Inc in Q4 2024 and held it in 1 quarter.
  • TD Asset Management's Septerna Inc position peaked at $1.59M in Q4 2024.
  • 71 funds tracked by Wall St. Rank held Septerna Inc as of Q1 2025.

Based on TD Asset Management's 13F filing for Q1 2025, filed 7 May 2025.